InveniAI Collaborates with Shionogi on AI-Based Drug Discovery

 InveniAI Collaborates with Shionogi on AI-Based Drug Discovery

InveniAI Collaborates with Shionogi on AI-Based Drug Discovery

Shots:

  • InveniAI is eligible to receive up to $200M/ program as up front, development, and commercial milestones along with royalties
  • The collaboration integrates InveniAI’s AI platform AlphaMeld to identify, evaluate, optimize novel targets with Shionogi’s expertise in developing and commercializing therapeutic modalities
  • Shionogi will synthesize targets identified by InveniAI for certain strategic diseases and will be responsible for developing, manufacturing, and commercializing the candidates

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Pharma Boardroom

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post